Xue Shao-An, Gao Liquan, Hart Daniel, Gillmore Roopinder, Qasim Waseem, Thrasher Adrian, Apperley Jane, Engels Boris, Uckert Wolfgang, Morris Emma, Stauss Hans
Department of Immunology and Molecular Pathology, University College London, Royal Free Hospital, Rowland Hill Street, London, NW3 2PF, United Kingdom.
Blood. 2005 Nov 1;106(9):3062-7. doi: 10.1182/blood-2005-01-0146. Epub 2005 Jul 14.
Cytotoxic T lymphocytes (CTLs) specific for an HLA-A2-presented peptide epitope of the Wilms tumor antigen-1 (WT1) can selectively kill immature human leukemia progenitor and stem cells in vitro. In this study we have used retroviral gene transfer to introduce a WT1-specific T-cell receptor (TCR) into T lymphocytes obtained from patients with leukemia and from healthy donors. TCR-transduced T cells kill leukemia cells in vitro and display WT1-specific cytokine production. Intravenous injection of TCR-transduced T cells into nonobese diabetic-severe combined immunodeficiency (NOD/SCID) mice harboring human leukemia cells resulted in leukemia elimination, whereas transfer of control T cells transduced with an irrelevant TCR was ineffective. The data suggest that adoptive immunotherapy with WT1-TCR gene-modified patient T cells should be considered for the treatment of leukemia.
对威尔姆斯瘤抗原-1(WT1)的HLA-A2呈递肽表位具有特异性的细胞毒性T淋巴细胞(CTL)在体外可选择性杀伤未成熟的人类白血病祖细胞和干细胞。在本研究中,我们利用逆转录病毒基因转移将WT1特异性T细胞受体(TCR)导入白血病患者和健康供体的T淋巴细胞中。TCR转导的T细胞在体外可杀伤白血病细胞,并表现出WT1特异性细胞因子的产生。将TCR转导的T细胞静脉注射到携带人类白血病细胞的非肥胖糖尿病-严重联合免疫缺陷(NOD/SCID)小鼠体内可导致白血病消除,而用无关TCR转导的对照T细胞转移则无效。这些数据表明,应考虑采用WT1-TCR基因修饰的患者T细胞进行过继性免疫治疗白血病。